Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy (Q42930914)

11 November 2017

title

Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy (English)

1 reference

non-small-cell lung carcinoma

11 November 2017

0 references

1 reference

1 reference

Francesco Grossi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20727457

20 June 2024

Giovanni Giuliani

1 reference

11 November 2017

Francesco Grossi

series ordinal

1 reference

11 November 2017

Filippo de Marinis

series ordinal

1 reference

11 November 2017

Stefan Walzer

series ordinal

1 reference

11 November 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20727457

20 June 2024

publication date

1 August 2010

1 reference

full work available at URL

11 November 2017

https://api.elsevier.com/content/article/PII:S0169500210701331?httpAccept=text/xml

1 reference

DOI

https://api.crossref.org/works/10.1016/S0169-5002(10)70133-1

https://api.elsevier.com/content/article/PII:S0169500210701331?httpAccept=text/plain

20 June 2024

1 reference

DOI

https://api.crossref.org/works/10.1016/S0169-5002(10)70133-1

20 June 2024

1 reference

11 November 2017

volume

69 Suppl 1

1 reference

11 November 2017

page(s)

S11-7

1 reference

Noninvasive staging of non-small cell lung cancer: a review of the current evidence.

11 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970133-1

7 January 2021

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970133-1

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970133-1

7 January 2021

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970133-1

7 January 2021

Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970133-1

7 January 2021

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970133-1

7 January 2021

Economics of treatments for non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970133-1

7 January 2021

Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970133-1

7 January 2021

Evidence-based outcomes for patients with advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970133-1

7 January 2021

Pharmacoeconomics of systemic therapies for lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970133-1

7 January 2021

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970133-1

7 January 2021

9164 An indirect comparison of the efficacy of bevacizumab plus cisplatin and gemcitabine (BCG) or bevacizumab plus carboplatin and paclitaxel (BCP) versus pemetrexed plus cisplatin (PC) and cetuximab plus vinorelbine and cisplatin (CVC) in patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970133-1

7 January 2021

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970133-1

7 January 2021

Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970133-1

7 January 2021

Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970133-1

7 January 2021

Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970133-1

7 January 2021

Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970133-1

7 January 2021

Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970133-1

7 January 2021

Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970133-1

7 January 2021

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970133-1

7 January 2021

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(10)70133-1

20 June 2024

Identifiers

DOI

1 reference

11 November 2017

1 reference